SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-105627
Filing Date
2021-04-05
Accepted
2021-04-05 08:03:30
Documents
13
Period of Report
2021-04-02
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d105468d8k.htm   iXBRL 8-K 24062
2 EX-99.1 d105468dex991.htm EX-99.1 9103
  Complete submission text file 0001193125-21-105627.txt   156169

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amrx-20210402.xsd EX-101.SCH 3062
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20210402_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20210402_pre.xml EX-101.PRE 10947
6 EXTRACTED XBRL INSTANCE DOCUMENT d105468d8k_htm.xml XML 3245
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 21803763
SIC: 2834 Pharmaceutical Preparations